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ABSTRACT
Arginine-rich cell-penetrating peptides (CPPs) are
promising transporters for intracellular delivery of
antisense morpholino oligomers (PMO). Here, we
determined the effect of L-arginine, D-arginine and
non-a amino acids on cellular uptake, splice-
correction activity, cellular toxicity and serum bind-
ing for 24 CPP2PMOs. Insertion of 6-aminohexanoic
acid (X) or b-alanine (B) residues into oligoarginine
R8 decreased the cellular uptake but increased the
splice-correction activity of the resulting compound,
with a greater increase for the sequences contain-
ing more X residues. Cellular toxicity was not
observed for any of the conjugates up to 10kM. Up
to 60kM, only the conjugates with 5 5 Xs exhibited
time- and concentration-dependent toxicity.
Substitution of L-arginine with D-arginine did not
increase uptake or splice-correction activity. High
concentration of serum significantly decreased the
uptake and splice-correction activity of oligoargi-
nine conjugates, but had much less effect on the
conjugates containing X or B. In summary, incor-
poration of X/B into oligoarginine enhanced the
antisense activity and serum-binding profile of
CPP PMO. Toxicity of X/B-containing conjugates
was affected by the number of Xs, treatment time
and concentration. More active, stable and less
toxic CPPs can be designed by optimizing the
position and number of R, D-R, X and B residues.
INTRODUCTION
Steric-blocking antisense oligonucleotides (AOs) are
considered potential therapeutics for genetic diseases
such as Duchenne muscular dystrophy (DMD) and
b-thalassemia. For their potential to be realized, however,
the AOs must be eﬀectively delivered to cell nuclei.
Cationic lipoplex- or PEI-based transfection methods used
to deliver charged AOs are not suitable for the delivery of
uncharged AOs such as phosphorodiamidate morpholino
oligomers (PMO, Figure 1) (1) and peptide nucleic acids
(PNAs) (2). Conjugation of PMO to short CPPs is a good
method to enhance the cytoplasmic and nuclear delivery
of PMO because the conjugates are simple to use and
because the short peptides and their AO conjugates can be
easily manufactured and characterized in a quality-
controlled manner. Examples of well-studied CPP PMO
conjugates include those with Tat and oligoarginine
peptides (3,4)
Important considerations in the design of eﬀective CPPs
include the ability to deliver AO eﬃciently, stability in
living systems and toxicity. We have reported that Tat and
oligoarginine peptides are not stable in human serum (5),
and are therefore ill-suited for in vivo applications.
Oligoarginine peptides incorporating non-a amino acids
have been proven superior to oligoarginine alone. CPPs
containing 6-aminohexanoic acid (X) and b-alanine
(B) were more stable in human serum than Tat or
oligoarginine peptides (5). A CPP PMO conjugate,
(RXR)4 PMO, has been shown to be more eﬃcient in
the correction of pre-mRNA mis-splicing (6) and in
inhibition of the replication of mouse hepatitis virus
in vivo (7) than an oligoarginine peptide. In addition,
(RXR)4 PMO conjugates have been shown to cause
eﬀective exon skipping in muscle cells from DMD dogs
(8), in human muscle explants (9) and in mdx mice (10), as
well as inhibiting the replication of various viruses in cell
cultures (7,11–13) and in mice (7,13).
The above studies have helped make it clear that
unnatural amino acids can confer enhanced stability and
activity, and therefore improve the potential of CPPs to
deliver therapeutic PMO. In pursuit of CPPs with
improved characteristics, we have carried out a struc-
ture–activity relationship study to investigate the eﬀects of
unnatural amino acid insertions in oligoarginine peptides
on cellular delivery, nuclear antisense activity, toxicity and
serum-binding characteristics of the resulting CPP PMO
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B and D-arginine (r). We chose to study the X amino acid
based on the successes of the (RXR)4 CPP in several
studies as shown in the previous paragraph. B and r amino
acids were chosen because they have good enzymatic
stability (5). The CPPs are (i) the oligoarginine sequences,
R8 and R9, (ii) sequences with RXR, RX and RB repeats,
as well as various combinations thereof, and (iii)
sequences containing D-arginine, r8, (rX)8 (rXR)4, (rXr)4
and (rB)8. The CPP PMO conjugates were evaluated for
their relative (a) cellular uptake, as determined by ﬂow
cytometry, (b) antisense activity, as determined by a splice
correction assay (13) and (c) cellular toxicity, as deter-
mined by MTT cell viability, propidium iodide membrane
integrity and hemolysis assays, as well as by microscopic
imaging.
MATERIALS AND METHODS
Synthesis ofCPP–PMO conjugates
CPP nomenclature and sequences are listed in Table 1.
Chemical structures of PMO and (RX)8 PMO are shown
in Figure 1. The antisense PMO (CCT CTT ACC TCA
GTT ACA) is designed to target a b-thalassemic mutant
splice site present in the human b-globin intron 2 of a
positive-readout antisense activity assay system (13) as
described in the Results section. Synthesis of PMO,
described previously (15,16), and the CPPs, using standard
Fmoc chemistry (17), were performed at AVI BioPharma,
achieving purities of490% as determined by HPLC and
mass spectrometry analysis. Conjugation of a CPP to a
PMO through an amide linker, described previously (6),
was followed with an additional puriﬁcation step to
remove nonconjugated peptide. Samples were loaded on
source 30S resin (Amersham Biosciences, Pittsburgh, PA)
in a 2ml Biorad (Hercules, CA) MT2 column at 2ml/min
with running buﬀer A (20mM Na2HPO4, 25% acetoni-
trile, pH 7.0) and puriﬁed into 45-s fractions with 0–35%
buﬀer gradient (buﬀer B: 1.5M NaCl, 20mM Na2HPO4,
25% acetonitrile, pH 7.0) over 60min, using a Biorad
BioLogic low pressure chromatography system. The
desired faction was desalted by a method described
previously (6). HPLC and MS analyses revealed that the
ﬁnal product contained 490% CPP conjugated to full-
length PMO, with the balance composed of CPP
conjugated to incomplete PMO sequence, nonconjugated
full-length or incomplete PMO.
Cellculture
The HeLa pLuc705 (pLuc705) (14) cell line was obtained
from Gene Tools, LLC (Philomath, OR). Human liver cell
line HepG2 was from American Type Culture Collection
(ATCC, Manassas, VA). Cells were cultured in RPMI
1640 medium supplemented with 2mM L-Glutamine,
100U/ml penicillin and 10% fetal bovine serum (FBS)
(HyClone, Ogden, UT) at 378C in a humidiﬁed atmo-
sphere containing 5% CO2. All treatments were carried
out in OptiMEM medium (Gibco, Inc., Carlsbad, CA.)
with or without FBS.
Celluptakeassay
pLuc705 cells were seeded 20h prior to treatment in
12-well plates at 100 000cells/well. Cells were treated with
2mM ﬂuorescein-tagged CPP PMO conjugates for 24h.
After treatment, cells were washed with 500mlo f
Table 1. Names and sequences of the CPPs
Name Sequence
  #o fX
Oligoarginine
R8 RRRRRRRRXB 1
r8 rrrrrrrrXB 1
R9 RRRRRRRRRXB 1
RX, RXR and RB panels
(RX)8 RXRXRXRXRXRXRXRXB 8
(rX)8 rXrXrXrXrXrXrXrXB 8
(RX)7 RXRXRXRXRXRXRXB 7
(RX)5 RXRXRXRXRXB 5
(RX)3 RXRXRXB 3
(RXR)4 RXRRXRRXRRXRXB 5
(rXR)4 rXRrXRrXRrXRXB 5
(rXr)4 rXrrXrrXrrXrXB 5
(RB)8 RBRBRBRBRBRBRBRBB 0
(rB)8 rBrBrBrBrBrBrBrBB 0
(RB)7 RBRBRBRBRBRBRBB 0
(RB)5 RBRBRBRBRBB 0
(RB)3 RBRBRBB 0
RX, RB, RXR and RBR mix panel
2 RBRBRBRBRBRXRBRXB 2
3a XRBRBRBRXRBRBRBRX 3
3b RXRRBRRXRRBRXB 3
3c RBRBRBRXRBRBRBRXX 3
3d RXRBRBRXRBRBRBRX 3
4a RBRBRBRBRXRXRXRXB 4
4b RBRXRBRXRBRXRBRXB 4
4c RXRRXRRXRRBRXB 4
 The sequences of peptides are written from N to C terminus.
R=arginine, r=D-arginine, X=6-aminohexanoic acid, B=
b-alanine. Each peptide had an acetyl group at the N-terminus and a
carboxyl group at the C-terminus.
Figure 1. Structures of PMO and (RX)8  PMO conjugate.
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10min and combined with 500ml medium containing 10%
FBS. Cells were spun down at 1000g for 3min, washed
with 500ml cold PBS twice, resuspended in 200ml of PBS
containing 1% FBS and analyzed by a FC-500 Beckman
Coulter cytometer (Fullerton, CA). Data was processed
using FCS Express 2 (De Novo Software, Thornhill,
Ontario, Canada).
Nuclear activity assay
pLuc705 cells were seeded 20h before treatment in 48-well
plates at 30 000cells/well. Cells were washed with 200ml
medium and treated with CPP PMO conjugates for 24h.
Cells were washed twice with 200ml PBS (HyClone,
Ogden, UT), and incubated with 100ml of cell lysis
buﬀer (Promega, Madison, WI) at 48C for 30min. Cell
lysate was separated from the cell debris by centrifugation
at 1000g for 10min at 48C. Luciferase levels were
determined by mixing 30ml of cell lysate and 50mlo f
luciferase assay reagent (Promega) and measuring sub-
sequent light production using a Flx 800 microplate
ﬂuorescence/luminescence reader (Bio-tek, Winooski,
VM). The relative light units (RLU) per sample were
normalized to microgram of sample protein as determined
by the bicinchoninic acid method, following the manu-
facturer’s procedure (Pierce, Rockford, IL).
Cellviability assayand microscopy
pLuc705 cells were seeded 20h before the treatment in
96-well plates at 9000cell/well and then treated with the
conjugates. The microscopic phase images of treated cells
were visualized by a Nikon Diaphot inverted microscope
(Melville, NY), captured by an Olympus digital camera
and processed by the Magnaﬁre software (Optronics,
Goleta, CA). After imaging the cells, the cell viability was
determined by the methylthiazoletetrazolium assay (MTT,
Sigma, St. Louis, MO) assay. MTT solution (5mg/ml) was
added to the treatment medium to a ﬁnal concentration of
0.5mg/ml and incubated for 4h at 378C. 85% of the
media of each well was then replaced with DMSO
containing 0.01M HCl and further incubated for 10min
at 378C and the absorbance measured at 540nm. Percent
cell viability was determined by normalizing the absor-
bance of each treated sample to the mean of untreated
samples.
Propidium iodide membrane integrityassay
pLuc705 cells were seeded 20h before treatment in 12-well
plates at 100 000 cells/well. Cells were treated by removing
the medium, washing with 500ml PBS and incubating with
medium containing CPP PMO conjugates. Treatment
medium was collected in tubes and cells were washed with
PBS once, and then treated with 400ml of 10% trypsin for
10min at 378C. Trypsin was neutralized with 500ml of the
serum containing medium. Cells were transferred to the
tubes containing previously collected treatment medium,
pelleted by centrifugation at 1000g for 5min, washed with
PBS once, and re-suspended in 200ml of 0.05mg/ml
propidium iodide (PI) in PBS. Cells were further incubated
at 378C for 15min and analyzed by the Beckman Coulter
cytometer (30 000 events/sample collected).
Hemolysis assay
The hemolytic activities of the conjugates were determined
in fresh rat blood according to a method described
elsewhere (18).
RESULTS
Cellular Uptake
Cellular uptake of CPP PMO conjugates was investi-
gated using the 30-carboxyﬂuorescein-tagged PMO
(PMOF) and ﬂow cytometry. We chose 2mM as the
treatment concentration because none of the conjugates
caused any detectable cytotoxicity at this concentration, as
demonstrated by the MTT and PI uptake assays. After
treating with the conjugates, cells were treated with trypsin
(19) to remove membrane-bound conjugates. We found
that a heparin sulfate washing step prior to trypsin
treatment did not remove additional membrane-bound
conjugates but caused some cellular toxicity (data not
shown); therefore, only the trypsin treatment step was
used in this study.
To determine the eﬀect of serum on cellular uptake of
the various conjugates, uptake evaluation assays were
carried out in the medium containing various concentra-
tions of, or in the absence of, serum. Cellular uptake of
CPP PMOF conjugates increased with the number of
arginines and decreased with the X and/or B residue
insertion (Figure 2A and B). The oligoarginine
R9 PMOF had a mean ﬂuorescence (MF) of 662,
nearly 3-fold higher than the 234 produced by
R8 PMOF, indicating that a diﬀerence of a single
arginine can make a substantial diﬀerence in the biological
properties of a CPP. Insertion of an X or B residue in the
R8 sequence reduced the MF from 234 of R8 PMO to 42,
70 and 60 of (RX)8 , (RXR)4  and (RB)8 PMOF,
respectively (Figure 2A). The number of RX or RB
repeats aﬀected cellular uptake, with conjugates having
fewer RX or RB repeats generating lower MF (Figure 2B).
While the addition of 10% serum to the medium caused
a decrease in the uptake of the R8  or R9 PMOF
conjugates, it increased the uptake of conjugates contain-
ing RX, RB or RXR motifs (Figure 2A and C). Serum
reduced the MF of R9  and R8 PMOF from 662 and
234 to 354 and 158, respectively, and increased the MF of
(RX)8 , (RXR)4  and (RB)8 PMOF from 41, 70 and
60 to 92, 92 and 111, respectively. These diﬀerences were
statistically signiﬁcant (Figure 2A). However, higher
serum concentrations (30 and 60%) decreased the
uptake of (RXR)4 PMOF and oligoarginine PMOF
(Figure 2C).
Arginine stereochemistry (D versus L) had little eﬀect on
the uptake of CPP PMOF conjugates. We compared the
MF of R8 , (RB)8  and (RX)8 PMOF with their
respective D-isomer conjugates, r8 , (rB)8  and
(rX)8 PMOF and found that there was no signiﬁcant
diﬀerence between each pair, as shown in Figure 2D for
the (RX)8  and (rX)8 PMOF pair.
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The eﬀectiveness of each CPP PMO conjugate was
determined in a previously described splicing correction
assay (14), considered a reliable method to assess nuclear
antisense activity of a steric-blocking AO. This assay
utilizes the ability of steric-blocking AOs to block a splice
site created by a mutation in order to restore normal
splicing. The luciferase coding sequence was interrupted
by the human b-globin thalassemic intron 2 which carried
a mutated splice site at nucleotide 705. HeLa cells were
stably transfected with the plasmid therefore named as
pLuc705 cell. In the pLuc705 system, steric-blocking AOs
must be present in the cell nucleus for splicing correction
to occur. Advantages of this system include the positive
readout and high signal-to-noise ratio. With this system
the relative eﬃciencies of various CPPs to deliver an AO
with sequence appropriate for splice-correction to cell
nuclei can be easily compared.
Oligoarginine, RX, RXR and RB panels. The CPP
conjugates with the highest nuclear antisense activities
were (RXR)4  and (RX)8 PMO. Figure 3A and B show
luciferase activity normalized to protein of cells treated
with various conjugates at 1 and 5mM for 24h. At both
concentrations, (RX)8  and (RXR)4 PMO were more
eﬀective than the other conjugates tested, with the
diﬀerence more prominent in serum-containing medium
at 1mM than at 5mM. Cells treated with 1mM of either
conjugate had luciferase activity 10–15-fold over the
background while the remaining conjugates yielded
about a 2–4-fold over the background (Figure 3A).
At 5mM, all conjugates generated higher luciferase activity
Figure 2. Cellular uptake of the CPP PMOF conjugates. pLuc705 cells were treated with carboxyﬂuorescein-tagged PMOs conjugated to CPPs in
OptiMEM with or without 10% serum for 24h, followed by ﬂow cytometry analysis. Data are presented as mean ﬂuorescence (MF) SD of six data
points from two independent experiments. (A) Cells treated with 2mMo fR 82,R 92, (RXR)42, (RX)82 or (RB)82PMOF conjugates. (B) Cells
treated with 2mM of (RX)82, (RX)72, (RX)52, (RB)82, (RB)72 or (RB)52PMOF conjugates in the absence of serum. (C) Cells treated with 2mM
of (RXR)42 or R92PMOF in media containing 0, 10, 30 or 60% serum. (D) Cells treated with (RX)82 or (rX)82PMOF in media containing
10% serum.
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again the most eﬀective, followed by (RB)8 PMO
(Figure 3B). Figure 3C shows that at 10mM, the activity
of RX or RB conjugates decreased as the number of RX
or RB repeats in the CPP decreased. The peptides with
5 or 3 RX or RB repeats, (RX)5, (RX) 3 (RB)5 or (RB)3,
generated much lower luciferase activity than those with
8 and 7 repeats.
Number and position of X residues. Having shown that
(RB)8 PMO had less activity than (RXR)4 PMO or
(RX)8 PMO, we further investigated the eﬀect of the
number and position of X residues on the activity of
conjugates. Eleven CPP PMO conjugates containing 0, 2,
3, 4, 5 or 8 Xs were compared (Figure 4). Generally, CPPs
containing a higher number of Xs had higher activities. At
2mM, (RX)8 PMO (8 X residues) had the highest activity
followed by (RXR)4 PMO (5 X residues) and the
conjugates with fewer Xs had lower activities. At 5mM,
three conjugates containing 3 (3d), 4 (4c) and 8 ((RX)8)X
residues had the highest activities, suggesting that the
position of X residues aﬀects activity.
L-Arginine versus D-arginine. Arginine stereochemistry
had little eﬀect on the nuclear activity of the R8  and
(RB)8 PMO conjugates but aﬀected the (RX)8 PMO
(Figure 5). Replacement of the eight L-arginine residues in
R8  or (RB)8 PMO with D-arginine residues did not
change the luciferase activity generated over the 1–5mM
(Figure 5A and B). However, the replacement did cause a
small but statistically signiﬁcant decrease in the activity
for (RX)8 PMO at 1mM( P=0.03) and 2mM( P=0.01)
(Figure 5C).
Serum effect on activity. The eﬀect of serum on the
antisense activity of the conjugates depended on the CPP
sequences, as shown in Figure 3A–D. Addition of 10%
serum to the medium decreased the activity of
oligoarginine PMO conjugates (R8 PMO and
R9 PMO) but increased activity of conjugates containing
Figure 3. Nuclear activity of CPP PMO conjugates: oligoarginine, RXR, RX and RB panels. pluc705 cells were treated with the conjugates
in OptiMEM medium with or without 10% serum for 24h. Nuclear activity of a conjugate is indicated by relative luciferase activity (RLU) per
microgram of protein. Data represent a mean SD of 6–9 data points from three independent experiments. (A) Cells treated with 1mMo fR 8 ,R 9 ,
(RB)8 , (RXR)4  or (RX)8 PMO. (B) Cells treated with 5mM of the same panel of conjugates. (C) Cells treated with 10mM of conjugates with 8, 7,
5 or 3 RX or RB repeating units. (D) Cells treated with (RXR)4  or R8 PMO at 1 or 5mM in 0, 10, 30 and 60% serum-containing medium.
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nearly doubled the luciferase activity of (RXR)4 , (RX)8 
and (RB)8 PMO at 5mM (Figure 3B). We further studied
this eﬀect for (RXR)4 PMO up to 60% serum. While the
activity almost doubled as the serum concentration
increased from 0 to 10%, it gradually decreased as the
serum concentration increased to 60%, at which activity
was similar tothatin 0%serum which was still signiﬁcantly
above the background. This ‘up and down’ proﬁle was also
observed with the 1mM (RXR)4 PMO treatment. Unlike
(RXR)4 PMO, the luciferase activity of R8 PMO or
R9 PMO (data not shown) only decreased as the serum
concentration increased, with an approximately 30%
reduction in 10% serum and no activity in 60% serum.
R8 PMO or R9 PMO did not display any detectable
activity at 1mM, regardless of the serum concentration
(data not shown).
Toxicity
The cellular toxicity of the various CPP PMO conjugates
was determined by MTT-survival, propidium iodine (PI)
exclusion and hemolysis assays and microscopic imaging.
The MTT and PI exclusion assays measure metabolic
activity and membrane integrity of cells, respectively. The
hemolysis assay determines compatibility with blood.
Microscopic images were used to verify the MTT results
and observe the general health of the cells.
MTT assay. pLuc705 cells were treated at concentrations
ranging from 2 to 60mM for 24h. As shown in Figure 6,
all conjugates, except (RX)8 and (RXR)4, had no toxicity
at up to 60mM. Up to 10mM, (RX)8 and (RXR)4
conjugates exhibited no toxicity, at higher concentrations
they reduced cell viability in a concentration-dependent
manner, with (RX)8 being more toxic than (RXR)4
(Figure 6C and D). Replacement of L-arginine with
D-arginine in R8 , (RB)8  and (RXR)4 PMO did not
change the viability proﬁles of these conjugates
(Figure 6A–C). Surprisingly, the L!D replacement in
(RX)8 PMO decreased the toxicity. Cell viability with
60mM treatment was 40% for (RX)8 PMO, but 80% for
(rX)8 PMO (Figure 6D). The eight conjugates containing
fewer than 5 X residues did not inhibit cell proliferation up
to 60mM (Figure 6E). Monomers of arginine or X,
individually or in combination, at 500mM each, produced
no inhibition of cell proliferation (Figure 6F). The
toxicities of the CPP PMO conjugates, (RXR)4 PMO,
3d PMO and 4c PMO, were also evaluated in human
liver HepG2 cells. We found that only (RXR)4 PMO
caused dose-dependent inhibition of cell proliferation
while other two conjugates had no toxicity up to 60mM,
the highest concentration tested in this study (data
not shown).
Microscopic images. We sought to verify the MTT results
by collecting microscopic images of cells treated with
60mM of the conjugates. The images correlated well with
the cell viability data. Images of (RX)8 , (rX)8 ,
(RXR)3RBR  (4c), (RXR)4 PMO and vehicle-treated
cells are shown in Figure 7. Cells treated with
(RX)8 PMO and (RXR)4 PMO appeared rounded and
detached from the culture well, and appeared to have
fewer live cells. Interestingly, cells treated with
(rX)8 PMO appeared to have normal morphology and
cell density. The replacement of one X of (RXR)4 PMO
Figure 5. Nuclear activity of CPP–PMO conjugates: D-arginine versus L-arginine. pluc705 cells were treated with the indicated compounds at 1, 2
and 5mM in OptiMEM containing 10% FBS for 24h. Data represent a mean of 9–12 samples from four independent experiments.
  Indicates that
diﬀerence in activity between the (RX)8 and (rX)8 PMO conjugates were statistically signiﬁcant.
Figure 4. Nuclear activity of CPP–PMO conjugates: number and
position of X residues. pluc705 cells were treated with the conjugates
having 0, 2, 3 (3a, 3b, 3c and 3d), 4 (4a, 4b and 4c), 5 and 8 X residues
(see sequences in Table 1) in OptiMEM medium with 10% serum for
24h. Nuclear activity of a conjugate is indicated by relative luciferase
activity (RLU) per microgram of protein. Data represent a mean SD
of 9–12 data points from four independent experiments.
Nucleic Acids Research, 2007, Vol. 35, No. 15 5187Figure 6. Toxicity of CPP PMO Conjugates: MTT assay. The cell viability is represented as the percent of viable pLuc 705 cells treated at 0, 2, 10,
20, 40 and 60mM of the indicated compounds. (A–E) in OptiMEM containing 10% serum for 24h. (F) Cells were treated with arginine (500mM) and
X (500mM) monomers independently and in combination (500mM R+500mM X). Data are represented as a mean of six data points obtained from
two independent experiments.
Figure 7. Toxicity of CPP PMO conjugates: microscopic images. pLuc705 cells were treated with the vehicle (No treatment), (RX)8 PMO,
(rX)8 PMO, (RXR)4 PMO or (RXR)3RBR PMO (4c) at 60mM in OptiMEM containing 10% serum for 24h and then directly visualized in the
culture medium under a microscope at  100magniﬁcation.
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(RXR)3RBR PMO (4c PMO)- treated cells had similar
density and morphology to the vehicle-treated cells.
Propidium iodine exclusion assay. The eﬀect of the
conjugates on integrity of cell membranes was investigated
by a propidium iodine (PI) exclusion assay. PI can only
permeate unhealthy/damaged membranes, so positive PI
ﬂuorescence indicates compromised cell membranes. Only
(RXR)4  and (RX)8 PMO conjugates were found to
signiﬁcantly aﬀect membrane integrity at higher concen-
trations (up to 60mM tested). Figure 8A shows the
histograms of pLuc705 cells treated with (RXR)4 PMO
at 60mM for 0.5, 5 and 24h. The PI positive (PI+) region
was deﬁned by the cells permeabilized with ethanol
(positive control) as indicated by the gate in the
histogram. The PI histogram shifts from the PI-negative
region to PI-positive region in the longer incubations,
indicating the conjugate caused membrane leakage in a
time-dependent manner. The 0.5- and 5-h-treatments
caused a slight shift towards the PI+ region, while the
24-htreatment produced a distinct peak which corre-
sponded to 57% of cells that were in the PI+ region.
Figure 8B shows the histograms of cells treated with
(RXR)4 PMO at concentrations of 2, 10, 20, 40 and
60mM for 24h. There was no signiﬁcant PI uptake at
concentrations up to 20mM. At higher concentrations, the
PI+ population appeared and the percentage of PI+ cells
increased as the treatment concentration increased,
indicating that there were more leaking cells at the
higher treatment concentration. Similar concentration-
and time-dependent PI uptake proﬁles were observed for
(RX)8 PMO but not for (RB)8 PMO and the remaining
conjugates (data not shown). Addition of 10% serum to
the treatment medium signiﬁcantly reduced membrane
toxicity for the (RXR)4  (Figure 8C) and (RX)8  PMO
conjugates (data not shown).
Hemolysis assay. The (RXR)4  and (RX)8 PMO con-
jugates were tested in a hemolysis assay and found to be
Figure 8. Toxicity of CPP–PMO conjugates: PI exclusion and hemolysis assay. All treatments were carried out in OptiMEM in the presence and
absence of 10% FBS. (A) Flow cytometry histograms of cell numbers versus PI ﬂuorescence of HeLa cells treated with 60mM of (RXR)4 PMO for
0.5, 5, and 24h in serum-free medium. Ethanol- treated cells are used as the positive control and the PI positive peak is indicated in the histogram.
(B) Flow cytometry histograms of cells were treated with (RXR)4 PMO at the concentration of 0, 2, 10, 20, 40 or 60mM for 24h in serum-free
medium. (C) Cells were treated with (RXR)4 PMO for 24h in the absence and presence of 10% FBS and then subjected to PI treatment and the
ﬂow analysis. (D) The level of hemoglobin (absorbance at 540nm) released from fresh rat red blood cells treated with (RXR)4 PMO, (RX)8 PMO,
PBS (negative control) or 0.005% of TX-100 (positive control) for 1h at 378C. The data represents a mean SD of four data points from two
independent experiments.
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were treated with the conjugates at 60mM, PBS (back-
ground) or 0.005% TX-100 (positive control). The super-
natants of conjugate- and PBS-treated samples had small
and similar amounts of free hemoglobin released,
far lower than that of the TX-100-treated samples
(Figure 8D).
DISCUSSION
The naturally occurring CPPs such as Tat peptide are not
stable in blood and neither are oligolysine/oligoarginine
(5), rendering these CPPs unfavorable as transporters for
therapeutic AOs. We reasoned that one approach to
improve stability would be to use non-a amino acids or
D-amino acids. In this study, we investigated whether
incorporation of 6-aminohexanoic acid (X), b-alanine (B)
and D-arginine (r) amino acids into the CPP would aﬀect
cellular delivery, antisense activity, toxicity and serum
binding of the resulting CPP PMO conjugates.
We found that CPP PMOF conjugates containing X/B
residues did not enter cells as eﬃciently as R8  and
R9 PMO conjugates. This is consistent with our previous
ﬁnding for the (RXR)4 conjugate (6). We have found that
cell surface proteoglycans were involved with binding of
the Tat ,R 9F2  and (RXR)4 PMO conjugates with the
(RXR)4 conjugate having the lowest binding aﬃnity.
Insertion of X into an oligoarginine CPP reduces the
charge density and may lead to decreased binding aﬃnity
for proteoglycans. Despite the lower cellular uptake
of X/B-containing CPP–PMO, they generated higher
antisense activities in the cell nucleus than
oligoarginine PMO. We have found that endocytosis
was the internalization mechanism (at least primarily) for
oligoarginine- and (RXR)4 PMO conjugates. Indication
of diﬀerent uptake mechanisms was not found among
these conjugates (6). Therefore we hypothesize that
X/B-containing conjugates have a greater ability to
escape from endosomes/lysosomes than oligoarginine
conjugates by a mechanism as yet to be studied.
The number of X residues aﬀects both the nuclear
antisense activity and the toxicity of conjugates. The
CPP PMO conjugate with 8 X residues [(RX)8 PMO]
had the highest activity followed by one with 5 Xs
[(RXR)4 PMO] (Figures 1 and 4). However, these
conjugates were toxic to cells at higher concentrations,
which may be a concern when considering potential
applications for in vivo delivery of PMO. Replacement of
all 8 Xs with Bs decreased both toxicity and antisense
activity. The combination of 3–4 Xs with several
B residues yielded CPPs with no detectable toxicity, and
at some concentrations several of them had similar
antisense activity as (RX)8 PMO. We think this type of
CPP, having Bs and fewer than 5 Xs, will oﬀer balanced
activity and low toxicity as well as the stability, and
have considerable potential for delivery of therapeutic
AOs. Further investigation into the toxicity and
activity versus dosing levels of these CPPs in vivo is
warranted.
Surprisingly, the replacement of L-arginine with
D-arginine enhanced neither uptake nor antisense activity
for oligoarginine, or X- and B-containing conjugates. In
the case of (RX)8 PMO, the replacement actually caused
a small but statistically signiﬁcant decrease in activity. Our
observation is diﬀerent from the results reported by others
(20,21) who found that D-CPPs had higher cellular uptake
than L-CPPs, although no biological functional cargo was
used in their study. The diﬀerence between results may be
due to the type and size of cargos and the cell lines used
for the assays. Whether the use of D-arginine-containing
peptides results in superior CPP PMO functional activity
in vivo remains to be tested.
We attempted to understand the nature of (RX)8  and
(RXR)4 PMO toxicity. It is apparent that these two
conjugates caused little immediate membrane damage
with 0.5 or 5h treatment at concentrations as high as
60mM (Figure 8). However, these two conjugates had
dose-dependent toxicity with 24 hr treatment as shown
by the leaky cell membranes and fewer cells compared
to controls (Figure 6C&D, Figure 8). Interestingly, the
replacement of Xs with Bs in (RX)8 PMO abolished the
toxicity, and the replacement of L-arginine with D-arginine
reduced the toxicity of (RX)8 PMO (Figure 6). We have
found that (rX)8 PMO was completely stable and the
peptide portion of (RB)8 PMO was only partially
degraded, whereas the peptide portion of (RX)8 PMO
was completely degraded in cells (5). We wondered
whether the diﬀerence in toxicity among (RX)8, (RB)8
and (rX)8 PMO conjugates was caused by diﬀerences in
intracellular stability, resulting in the metabolized prod-
ucts of (RX)8 PMO producing toxicity. The identiﬁable
metabolized products of (RX)8 PMO were XRXB PMO
and XB PMO (5) but neither product had any detectable
toxicity as measured by MTT assay (data not shown). It is
possible that the CPP portion was degraded into free
amino acids and/or smaller peptide fragments which were
toxic. However, our investigation revealed that neither
free R nor X, alone or in combination, caused cellular
toxicity. Another possibility is that because of the high
hydrophobicity of X compared to B, X in combination
with positively charged arginine residues leads to toxicity
not generated by B residue combinations. However, this
explanation does not account for the diﬀerence in toxicity
observed between (RX)8 PMO and (rX)8 PMO, which
have the same hydrophobicity. Perhaps the toxicity of
(RXR)4 PMO and (RX)8 PMO was caused by the
peptide fragments that we could not identify by mass
spectrometry.
Unlike the toxicity diﬀerence between (RX)8  and
(rX)8 PMO, the L!D replacement did not change the
toxicity of (RXR)4 PMO (Figure 6). Substitution of
either one R (rXR) or two R (rXr) from the RXR repeat
neither reduced nor increased the toxicity proﬁle of
(RXR)4 PMO. At this point, we do not fully understand
the mechanisms of (RXR)4  and (RX)8 PMO conjugate
toxicity, but look forward to studying this topic further.
Serum eﬀect on the activity of a CPP AO conjugates is
an important issue when considering potential in vivo
applications. X/B-containing conjugates were still active
in 60% serum while oligoarginine conjugates were not.
5190 Nucleic Acids Research, 2007, Vol. 35, No. 15The greater stability of the X/B-containing conjugates to
serum enzymes is likely a factor contributing to their high
activity. The loss of activity in high serum concentrations
makes oligoarginine CPPs undesirable as potential ther-
apeutic AO carriers.
In summary, we have found that the X/B-containing
CPP PMO conjugates are superior to oligo-
arginine PMO conjugates for the following reasons:
they display higher activity in cell nuclei, are less aﬀected
by serum and are more stable in blood (5). The toxicity of
the X/B-containing CPPs can be reduced by keeping
the number of X residues below 5 while still maintaining a
reasonable delivery eﬃcacy and stability. This study
provides a basis for further optimization of CPP sequence
using R, r, X and B residues in the interest of further
reducing toxicity and increasing antisense activity, which
will likely lead to more eﬀective AO transporters for
potential therapeutic applications.
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